[Retracted] Meta-Analysis of the Effectiveness and Safety of Glucocorticoid for the Treatment of IgA Kidney Disease

Table 1

Overall efficacy of hormone in the treatment of IgA nephropathy proteinuria.

Glucocorticoid group				Control group			Std. mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, fixed, 95% CI
Kobayashi et al., 1996	0.8	0.5	20	1.5	1.3	26	8.6%	−0.67 [−1.27,−0.07]
Shoji et al., 2000	0.29	0.23	11	0.71	0.39	8	2.9%	−1.31 [−2.33,−0.29]
Locatelli et al., 2001	0.67	0.5	43	1.48	1.87	43	16.5%	−0.59 [−1.02,−0.15]
Uzu et al., 2003	−1.26	0.56	23	−0.86	0.45	22	8.4%	−0.77 [−1.38,−0.16]
Moriyama et al., 2004	1.02	0.98	20	1.28	2.19	40	10.7%	−0.14 [−0.67, 0.40]
Hogg et al., 2006	−1.26	0.56	34	−0.86	0.45	31	12.1%	−0.77 [−1.28, −0.27]
Koike et al., 2008	0.31	0.51	24	0.68	0.69	24	9.2%	−0.60 [−1.18, −0.02]
Lv et al. 2009	−2.5	0.9	33	−2	0.8	30	12.1%	−0.58 [−1.08, −0.07]
Manno et al., 2009	1.2	2.5	48	1.4	2.3	49	19.5%	−0.08 [−0.48, 0.32]
Total (95% CI)			256			273	100.0%	−0.51 [−0.68, −0.33]

Heterogeneity: Chi-squared = 10.93, df = 8 (P = 0.21); F = 27%; test for overall effect: Z = 5.65 (＜0.00001).